Clinical evaluation of Lenampicillin (LAPC) in the oral infections

Makoto Nakanishi, Katsuhisa Hukuyama, Nobuyoshi Mizukawa, Koji Uematsu, Katsumi Nishijima

Research output: Contribution to journalArticlepeer-review


Lenampicillin (LAPC), an oral antimicrobial agent of a Penicillin derivative, was evaluated clinically in 58 cases with oral infections such as periodontitis, pericoronitis and osteitis of jaw. The daily dose of 750-1500 mg was used, and the following results were recorded. 1) The clinical efficacy rate was 91.4 % according to the numerical rating on the 3 rd day of the treatment, and 89.6% by the judgement of the doctor-in-charge. 2) Side effects were observed in 3 cases (5.2 %). However, the symptoms were not serious. No abnormal change was noted. 3) A total of 66 strains were isolated from the pus of abscesses, of which 30 strains (45.5 %) were anaerobes, indicating the important role of anaerobes in oral infections. 4) The aerobes consisted predominately of Oral Streptococci. The anaerobes consisted largely of Peptostreptococci and Bacteroides. 5) ABPC demonstrated high effectiveness on the isolated organisms. In contrast, OFLX and CCL had little effect on the isolated organisms.

Original languageEnglish
Pages (from-to)8-19
Number of pages12
Issue number1
Publication statusPublished - 1991


  • Clinical efficacy
  • Lenampicillin (LAPC)
  • Oral infection

ASJC Scopus subject areas

  • Dentistry(all)
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Clinical evaluation of Lenampicillin (LAPC) in the oral infections'. Together they form a unique fingerprint.

Cite this